Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-02-11

Clinical Trial Update: BATTLE Program: Sorafenib in Patients With NSCLC [Phase 2]

View source ↗

Summary

The BATTLE program's Phase 2 study of sorafenib in non-small cell lung cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nexavar (Sorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-11